24Nov 2023
Effects of Once-Weekly GLP-1 Receptor Agonists and DPP-4 Inhibitors in People with Diabetes and Cardiovascular Diseases

Effects of Once-Weekly GLP-1 Receptor Agonists and DPP-4 Inhibitors in People with Diabetes and Cardiovascular Diseases

This observational cohort study compared the real-world effects of once-weekly GLP-1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 inhibitors (DPP-4is) in adults with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD). Among new users, OW GLP-1 RA users showed a 26%, 22%, and 24% lower risk of ischemic stroke, myocardial infarction, and their composite, respectively, compared to DPP-4i users. Additionally, OW GLP-1 RA users exhibited lower cardiovascular-related and all-cause healthcare resource utilization and costs compared to DPP-4i users. These findings suggest potential cardiovascular benefits and cost-effectiveness associated with OW GLP-1 RAs in this population.

  • #endo-diabetology

Like

Save

Share